DNA enzyme and application thereof

By providing a DNA enzyme system containing 13PD catalytic domain, the problem of long single-strand DNA synthesis in the prior art is solved, and oligonucleotide generation with high yield and accuracy is achieved, meeting the needs of biomedical research.

CN119032173APending Publication Date: 2024-11-26SHANGHAI CANGYU BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380032584.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-08
Filing Date
2023-04-07
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

It is difficult for the existing technology to effectively synthesize and apply long single-stranded DNA, and the existing methods have low yields and high costs, making it difficult to meet the needs of biomedical research.

Method used

A DNA enzyme system is provided, comprising a catalytic domain and a substrate domain. The catalytic domain comprises a 13PD catalytic domain sequence, which is capable of cleaving the substrate domain at a cleavage site, and the substrate domain comprises A on the 3' side, C and G bases are used to generate cleavage products with customizable 5' and/or 3' ends.

Benefits of technology

The high yield and accurate generation of oligonucleotides of different lengths is achieved, which solves the problem of long single-stranded DNA synthesis and improves the efficiency and economicality of biomedical applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005070956590000191
    Figure BDA0005070956590000191
  • Figure HDA0005070956600000011
    Figure HDA0005070956600000011
  • Figure HDA0005070956600000021
    Figure HDA0005070956600000021
Patent Text Reader

Abstract

The invention provides a DNA enzyme and application thereof. The present disclosure also provides a system comprising one or more catalytic domains and one or more substrate domains.
Need to check novelty before this filing date? Find Prior Art

Description

Background Art At present, DNA nanotechnology has a wide demand for single-stranded DNA (ssDNA), especially long single-stranded DNA (>100 bases) in biomedical research fields such as knock-in. However, due to the limitations of chemical synthesis methods, it is difficult to synthesize long single-stranded DNA. In addition, in practical applications, methods known in the art all have the problems of low yield and high cost. Summary of the invention The present disclosure provides a DNA enzyme system for preparing long single-stranded DNA. The system can robustly generate cleavage products with customizable 5' and / or 3' ends. The products disclosed herein can show robust effects when cutting a series of oligonucleotides of different lengths, with high yield and accuracy. In one aspect, the present disclosure provides a system comprising one or more catalytic domains and one or more substrate domains, wherein the catalytic domain comprises a 13PD catalytic domain sequence, the catalytic domain cleaves the substrate domain at a cleavage site, and the substrate domain comprises a base selected from A, C and G on the 3' side of the cleavage site. On the one hand, the present disclosure provides a nucleic acid comprising one or more catalytic domains and one or more substrate domains, wherein the catalytic domain comprises a 13PD catalytic domain sequence, the catalytic domain cleaves the substrate domain at the cleavage site, and the substrate domain comprises a base selected from A, C and G on the 3' side of the cleavage site. In one aspect, the present disclosure provides a vector comprising the system of the present disclosure and / or the nucleic acid of the present disclosure. In one aspect, the present disclosure provides a cell comprising the system of the present disclosure, the nucleic acid of the present disclosure and / or the vector of the present disclosure. In one aspect, the present disclosure provides a composition comprising the system of the present disclosure, the nucleic acid of the present disclosure, the vector of the present disclosure and / or the cell of the present disclosure. In one aspect, the present disclosure provides a kit comprising the system of the present disclosure, the nucleic acid of the present disclosure, the vector of the present disclosure, the cell of the present disclosure, and / or the composition of the present disclosure. In one aspect, the present disclosure provides a method for preparing a product, which comprises providing a system, a nucleic acid, a vector, a cell, a composition and / or a kit of the present disclosure. In one aspect, the present disclosure provides a product prepared according to the method of the present disclosure. In one aspect, the present disclosure provides a combination comprising providing a 2+ and about 5mM to 20mM Mn 2+ conditions. In one aspect, the present disclosure provides a method for preparing a product, the method comprising providing a combination of the present disclosure and a 5' nucleic acid cutter and a 3' nucleic acid cutter. In one aspect, the present disclosure provides a product prepared according to the method of the present disclosure. In one aspect, the present disclosure provides a method for detecting nucleic acid, which comprises providing a product of the present disclosure. In one aspect, the present disclosure provides a sequencing method, the method comprising providing a product of the present disclosure. In one aspect, the present disclosure provides a genetic engineering method, the method comprising providing a product of the present disclosure. In one aspect, the present disclosure provides a data storage method, which includes providing a product of the present disclosure. Other aspects and advantages of the present disclosure will be apparent to those skilled in the art from the following detailed description, in which only illustrative embodiments of the present disclosure are shown and described. It will be appreciated that the present disclosure is capable of other different embodiments, several details of which may be modified in various obvious aspects without departing from the present application. Therefore, the drawings and description are to be regarded as illustrative and non-restrictive in nature. Incorporated by Reference All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. BRIEF DESCRIPTION OF THE DRAWINGS The novel features of the present invention are set forth in detail in the appended claims. The features and advantages of the present invention will be better understood by reference to the following detailed description and accompanying drawings which set forth exemplary embodiments utilizing the principles of the present invention, wherein (also referred to herein as "figures" and "FIG."): Figure 1 PECAN is a biotechnological method for preparing arbitrary DNA sequences by paired-end cleavage using DNA enzymes. a, Schematic diagram of the PECAN scheme. b, Previously reported DNA enzymes 9Sequence and secondary structure of 13PD1. After screening, this DNA enzyme was selected as DNA enzyme 1. Its cleavage site is highlighted with scissors. c, Sequence and secondary structure of another previously reported DNA enzyme II-R1 and its mutants II-R2 & R3 identified by reselection in this work. The mutated nucleotides are labeled. II-R2 and II-R3 can be selectively used as DNA enzyme 2. d, Kinetic characterization of 5' and 3' self-cleavage by denaturing PAGE (dPAGE) analysis. Solid arrows and hollow arrows refer to uncut DNA and cut DNA, respectively. e, Time relationship diagram of the DNA cleavage portion of 13PD1 and its mutants. Data were extracted from the gel in d. k obs The 1-hour yield values ​​show that the identity of the single nucleotide at the 3′ of the cleavage site (default T in 13PD1) has a moderate effect on the cleavage rate, but does not affect the 1-hour cleavage yield (>85% for T, A, G, and C). f, Time-dependent plot of the DNA cleavage fraction of II-R1, R2, and R3. From d and Figure 8 and 9 The data were extracted from the gels. The k obs The and 1 hour yield values ​​indicate that II-R2 & R3 are more robust than II-R1. For II-R2, a yield of more than 85% was obtained within 1 hour because the single nucleotide identity at the 5′ of the cleavage site was G, A or C, rather than T (63±3% yield). The problem of the lower effectiveness of T in II-R2 on the yield was solved by replacing II-R2 with II-R3, which cuts directly after T with a 1 hour yield of 88±2%. The standard deviation (SD) of the yields in e and f is generated from three replicates. The check mark indicates each DNA enzyme suitable for PECAN. Figure 2Comparison of PECAN oligonucleotides with CS oligonucleotides is shown. a, Representative 71nt DNA is compared by dPAGE analysis. Markers 1 and 2: 20nt ladder band and 50nt ladder band, respectively. b, 71nt DNA is compared by monoisotope spectroscopy. The observed molecular weight (MW) of CS 71mer (21667.9Da) and PECAN 71mer (21668.2Da) matches the calculated value (21667.5Da) well. In addition to the main mass peak, many weak peaks (circled with dashed circles) appeared around the main mass peak of CS 71mer. c, Representative 65nt and 69nt oligonucleotides are compared by dPAGE analysis. d, Sequence and secondary structure information and full-length purity of three representative oligonucleotides. The comparison between CS and PECAN is based on NGS with >1000000 reads per time. e, Workflow for RNA in situ imaging using PLP DNA. f, HER2 expression in MCF-7 and CCNB1 expression in SK-BR-3 cells detected by CS and PECAN PLP. Detected mRNAs are shown as dots. Cell nuclei stained with DAPI are shown in blue. g, Statistical graphs of RCP per cell for HER2 and CCNB1 detected by CS and PECAN PLP. Two-tailed paired Student's t-test P value indicates statistical significance (****P<0.0001). h, Multiple mRNA expression in HER2-positive breast cancer FFPE tissue sections detected by CS and PECAN PLP. Combined detection of HER2, MKI67, ESR1, and PGR expression. A magnified view (boxed area) is shown on the right side of each tissue section. Scale bar: 100 μm. i, Statistical graphs of RCP per cell for HER2, MKI67, ESR1, and PGR in tissue sections detected by CS and PECAN PLP. Figure 3Figure 3 shows the generation of LASSO probes by PECAN for the analysis of RNA splice variants. a, Alternative splicing patterns of S100P and CYP24A1 in 97L and NL cells. b, Schematic diagram of single target capture using LASSO probes. LASSO 1 and 2 were specifically designed for S100P and CYP24A1 tv1, respectively. c, Quality check of LASSO probes generated by PECAN. M3: 200 nt ladder. LASSO 1: 335 nt. LASSO 2: 550 nt. d, Gel analysis after capture of targeted amplification products. LASSO 1 and 2 were programmed to capture 401 bp and 749 bp fragments in S100P and CYP24A1 tv1 transcripts, respectively. Unexpected bands are indicated by *. NL samples were used as negative controls. M4: 100 bp ladder. e, Sequencing of captured targets. Transcripts for S100P and CYP24A1 tv1 were confirmed in 97L. Another isoform of CYP24A1, named CYP24A1 tvX1, was also found in 97L, which contains a 172 bp insertion between exons 11 and 12. f, Screening of CYP24A1 splicing isoforms in a panel of hepatocellular carcinoma cell lines using PECAN LASSO 2. Figure 4The generation of gene-sized HDRT by PECAN is shown for precise and efficient genome editing. a, Schematic diagram of HDR-guided knock-in. dsDNA breaks are formed at specific sites in genomic DNA using the CRISPR / Cas9 system. During the HDR process, either dsDNA or ssDNA with homology arms can be used as templates (HDRT) to insert exogenous sequences into genomic DNA. b, Two 1570nt DNAs generated by a commercial chain enzyme kit (Kit) and PECAN were compared by dPAGE analysis. + and - refer to the sense strand and antisense strand, respectively. M3: 200NT ladder band. c, Confocal microscopy imaging of endogenous fluorescence in Hek293T cells, KI was performed using HDRT of dsDNA, Kit ssDNA, and PECAN ssDNA. Fusion protein tags include mEGFP on TUBA1B (tubulin α1b), mCherry on CLTA (clathrin light chain A), mEGFP on FBL (fibrillin), and BFP on RAB11A (Rab protein 11A). Obvious off-targets are indicated by arrows. d, Representative flow cytometry plots showing off-target efficiencies of dsDNA, Kit+, and PECAN+HDRT in Hek293T cells. The experiment was performed with Cas9 without sgRNA. e, Comparison of apparent KI efficiencies of dsDNA, Kit+, and PECAN+HDRT in Hek293T and H9 cells. f, Confocal microscopy imaging of endogenous fluorescence in Hek293T cells with KI dual-labeled with dsDNA and PECAN+HDRT. In each panel, the visualized mEGFP and mCherry labels are shown in the upper right and lower right corners, respectively, and the merged view is shown on the left. g, Reconstructed 3D image (i) shows the colocalization of TDN with microtubules in Hek293T cells. The location of TDN-Cy5 was determined by 3D optical sectioning (ii-iv). h, Three-color confocal microscopy colocalization of TDNs-Cy5 in Hek293T cells at different stages of the cell cycle. Scale bar: 10 μm. Figure 5 Figure 2. Schematic diagram of a PECAN oligonucleotide-based data storage system. Figure 2. Comparison of features of current DNA-based storage systems. Figure 6I-R3 is shown as an imperfect DNA enzyme 1 for PECAN. a, Sequence and secondary structure of I-R3, previously reported DNA enzymes and potential DNA enzyme 1 for PECAN. Its cleavage site is highlighted with scissors. b, Analysis of the cleavage activity of I-R3' for all 16 combinations of two nucleotides at ^AG-3' by dPAGE. c, Analysis of the cleavage activity of I-R3' for the ^AG-3' to ^N-3' mutation by dPAGE. d, Re-examination of the cleavage site of I-R3 for the sequence of ^NG-3'. All gels were stained for band analysis. Yields and SDs were generated from three replicates. Figure 7 The programmability of the first nucleotide in the stem downstream of ^N-3' of 13PD1 and its mutants is shown. Schematic diagram of the covariation of 13PD1, 13PD1-A (^A-3'), 13PD1-G (^G-3') and 13PD1-C (^C-3'), and the dPAGE analysis of the corresponding cleavage activity. All gels were stained for band analysis. Yields and SDs were generated from three replicates. Figure 8 Reselection on II-R1 is shown. a, Kinetic characterization of II-R1 (5′-G^) and its mutants II-R1-A (5′-A^), II-R1-T (5′-T^) and II-R1-C (5′-C^) by dPAGE. b, Schematic diagram of the creation of a degenerate DNA library for II-R1 reselection. Based on reselection, we constructed a consensus sequence and secondary structure model for class II DNA enzymes. Gray, black and red nucleotides represent at least 75%, 90% and 97% conservation, respectively. Less conservative nucleotides are represented by circles. Green shading indicates base pairs supported by covariation. R refers to purine. c, Sequences of II-R1 and II-R2 and IIR3 mutants that can cut faster. Dots represent identical nucleotides. Gray shading indicates the sequences that form the P1 and P2 stems. Arrows point to the cleavage site. And the 5′ nucleotides of the II-R2 and II-R3 cleavage sites are highlighted. Fig. 9 Characterization of II-R2 and II-R3 is shown. a, Kinetic characterization of II-R2-T (5′-T^) by dPAGE analysis. b, Schematic diagram of covariation of II-R2-G (5′-G^), II-R2-A (5′-A^), II-R2-C (5′-C^) and II-R3 (5′-T^), and dPAGE analysis of the corresponding cleavage activities. The gels in be were stained for band analysis. Yields and SDs were generated from three replicates. Fig.10Identification of optimal metal ion conditions for robust co-hydrolysis of II-R2 / 3 and 13PD1 is shown. a, In the presence of different concentrations of Zn 2+ and Mn 2+ The activities of II-R2-G and 13PD1 were tested in a buffer solution (pH 7.0 at 23°C). For II-R2-G only, the default metal requirement is 2 mM Zn 2+ ; For 13PD1, the optimal metal condition was 1 mM Zn 2+ and 20 mM Mn 2+ After testing and analysis, 1mM Zn 2+ and 5 mM Mn 2+ The optimal metal ion concentration for both enzymes in one pot was determined to allow robust cleavage of each enzyme. 1 mM Zn 2+ and 5 mM Mn 2+ To ensure that the cleavage yield of both enzymes exceeds 90%, it is recommended to incubate at 37 °C for 2 h. b, confirming that 1 mM Zn 2+ and 5 mM Mn 2+ Optimal conditions for II-R2-A, II-R2-C, II-R3, and 13PD1-A / G / C. Fig.11 Examples of programming DNA enzyme sequences into customized oligonucleotides for PECAN generation are shown. a, 13PD1 is paired with II-R2-C to generate a 71mer oligonucleotide. b, 13PD1 is paired with II-R3 to generate a 1390mer oligonucleotide. Fig.12 An example of collecting ss-phagemid precursors for PECAN generation of customized oligonucleotides is shown. a, Phagemid precursors are collected in a culture dish. From top to bottom, the precursors carry customized sequences of 71nt, 1390nt, and 6790nt. The samples are lyophilized and weighed. b, Denaturing gel shows almost complete release of target oligonucleotides from recombinant phagemid precursors after PECAN treatment. Note that only a small portion of the DNA sample in a was PECAN treated and shown in b. Fig.13 Error distribution of CS and PECAN oligonucleotides is shown. ac, Comparison between CS and PECAN 65mer, 69mer and 71mer oligonucleotides. Analysis based on NGS data. Mutation (deletion mutation) x refers to an oligonucleotide sequence with x mutated (inserted or deleted) nucleotides. Fig.14Quality check of PLPs generated by PECAN is shown. a, dPAGE analysis of PLPs used for RNA imaging in cells. M1: 20NT ladder. b, dPAGE analysis of PLPs used for RNA imaging in tissue samples. c, Sequences of all PLPs used in this study. Fig.15 Detection of multiple mRNA expression in HER2-positive breast cancer FFPE tissue sections is shown. a, Detection by CS PLP. b, Detection by PECAN PLP. HER2: red; MKI67: cyan; ESR1: yellow; PGR: green. Cell nuclei stained with DAPI are shown in blue. Figure 2 h shows a merged view and a magnified view (boxed area) of four RNAs. Scale bar: 100 μm. Fig.16 Analysis of sequencing data of captured fragments is shown. a, Sequences captured from 97L by PECAN LASSO 1. b and c, Sequences captured from 97L by PECAN LASSO 2. Fig.17 Quality check of PECAN and Kit HDRT by dPAGE is shown. M3: 20 NT ladder. Arrows point to the putative highly structured and immutable DNA. Fig.18 The relationship between cell viability of PECAN HDRT and dsDNA HDRT is shown. a, The number of viable cells under the microscope was significantly reduced after electroporation with dsDNA HDRT compared to PECAN HDRT. b, The relationship between cell viability and DNA dosage when KI was performed using dsDNA HDRT, PECAN+HDRT, and PECAN-HDRT. The experiment was performed in Hek293T cells. Fig.19 The measurement of on-target GFP frequency at the TUBA1B locus by ddPCR assay is shown. a, Schematic diagram of the measurement strategy. RPP30 was selected as a reference gene to test ddPCR conditions. b, One-dimensional fluorescence amplitude plot of ddPCR amplification products. Droplets that produce close to background signals are represented by gray dots. c, Calculated concentrations of gene fragments detected by ddPCR (copies / μl). d, Estimated on-target integration of mEGFP to TUBA1B of PECAN and Kit HDRT. DETAILED DESCRIPTION

[0001] Although various embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that these embodiments are provided by way of example only. Many variations, changes and alternatives may occur to those skilled in the art without departing from the present invention. It should be understood that various alternatives to the embodiments of the present invention described herein may be employed. The term complementary as used herein generally refers to the formation of base pairs between nucleic acids. Oligonucleotides and their analogs hybridize by hydrogen bonding between complementary bases, which hydrogen bonding includes Watson-Crick hydrogen bonding, Hoogsteen hydrogen bonding or reverse Hoogsteen hydrogen bonding. Generally, nucleic acid molecules are composed of nitrogenous bases, which are either pyrimidines (cytosine (C), uracil (U) and thymine (T)) or purines (adenine (A) and guanine (G)). These nitrogenous bases form hydrogen bonds between pyrimidines and purines, and the bonding of pyrimidines to purines is called "base pairing". More specifically, A will hydrogen bond with T or U, and G will bond with C. Artificial or naturally modified nitrogenous bases may be involved. For example, pseudoisocytosine (J) or 5-methylcytosine (5mC) will hydrogen bond with G. "Complementary" refers to the base pairing that occurs between two different nucleic acids or between two different regions of the same nucleic acid. "Specifically hybridizable" and "specifically complementary" are terms indicating a degree of complementarity sufficient to allow stable and specific binding between a nucleic acid (or its analog) and another nucleic acid target (e.g., DNA or RNA). A nucleic acid or analog may (but need not) be 100% complementary to its target sequence in order to be specifically hybridizable. For example, a nucleic acid molecule specifically binds to another nucleic acid molecule if a sufficient number of nucleic acid molecules form base pairs or hybridize with its target nucleic acid molecule to allow detection of the binding (such as at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% complementary). The term catalytic nucleic acid as used herein generally refers to a nucleic acid molecule that can catalyze a specific chemical reaction (such as oxidative cleavage or hydrolytic cleavage, e.g., phosphodiester hydrolytic cleavage, nucleoside excision, phosphorylation (or dephosphorylation), ligation or other reactions). Catalytic nucleic acids include ribozymes (catalytic RNA or ribonucleases). The term deoxyribozyme (DNA enzyme) as used herein generally refers to a DNA molecule that can catalyze a specific chemical reaction. DNA enzymes can catalyze nucleic acid cleavage (such as oxidative cleavage or hydrolytic cleavage, such as phosphodiester hydrolytic cleavage), nucleoside excision, phosphorylation (or dephosphorylation), conjugation or other reactions. DNA enzymes may or may not have one or more non-natural chemical modifications on nitrogenous bases and / or their backbones. DNA enzymes (catalytic DNA or deoxyribozymes) and other natural or non-natural, modified or unmodified nucleic acid molecules. The term single-stranded nucleic acid as used herein generally refers to a nucleic acid that includes only a single polymer chain (e.g., a nucleic acid polymer chain that does not form a non-covalent bond with another nucleic acid polymer), such as single-stranded DNA (ssDNA). Nucleic acid molecules can be completely single-stranded (e.g., ssDNA formed by melting double-stranded DNA molecules) or partially single-stranded (e.g., ssDNA regions formed by damage and / or enzymatic activity). The term vector used herein generally refers to a nucleic acid molecule that is introduced into a host cell to produce a transformed, transfected or transduced host cell. A vector may contain a nucleic acid sequence that allows it to replicate in a host cell, such as an origin of replication. On the one hand, the present application provides a system comprising one or more catalytic domains and one or more substrate domains, wherein the catalytic domain comprises a 13PD catalytic domain sequence, the catalytic domain cleaves the substrate domain at a cleavage site, and the substrate domain comprises a base selected from A, C and G on the 3' side of the cleavage site. For example, the catalytic domain can be the catalytic domain of a DNA enzyme. The substrate domain can be a nucleic acid product to be prepared, or the substrate domain can be a part of a nucleic acid product to be prepared, or the substrate domain can be the 5' part of a nucleic acid product to be prepared. Not all DNA enzymes can generate any user-defined 5' end of a substrate domain or a nucleic acid product. For example, it is expected that the 5' end of a substrate domain that changes will cause the catalytic domain of a DNA enzyme to lose its cutting ability. The reason may be that the 5' end of the substrate domain has a conservative nucleotide, and the conservative nucleotide may be a "scar" on the nucleic acid product. Surprisingly, 13PD, one of many DNA enzymes, can produce a substrate domain or a nucleic acid product with a 5' end that is A, C or G instead of T. For example, the system can include one or more catalytic nucleic acids, and the catalytic nucleic acids include one or more catalytic domains. For example, wherein the system can include one or more substrate nucleic acids, and the substrate nucleic acids include one or more substrate domains. For example, one or more of these catalytic nucleic acids are separated and / or conjugated with one or more of these substrate nucleic acids.For example, wherein one or more of these catalytic nucleic acids are connected with one or more of these substrate nucleic acids via one or more nucleotides containing any kind of base. For example, the system further comprises one or more binding domains, and the binding domains are located on both sides of and / or within the catalytic domain and / or the substrate domain. For example, the catalytic nucleic acid comprises one or more binding domains A, the substrate nucleic acid comprises one or more binding domains B, and the binding domain A is capable of binding to the binding domain B. For example, the catalytic nucleic acid comprises a binding domain A-5 located at the 5' side of the catalytic domain and a binding domain A-3 located at the 3' side of the catalytic domain, the substrate nucleic acid comprises a binding domain B-5 located at the 5' side of the substrate domain and a binding domain B-3 located at the 3' side of the substrate domain, and the binding domain A-5 is complementary to the binding domain B-3 and / or the binding domain A-3 is complementary to the binding domain B-5. For example, the 13PD includes 13PD1, 13PD2, 13PD3, 13PD4 and / or mutants thereof. For example, the catalytic domain includes the sequence of SEQ ID NO: 17. For example, the catalytic domain includes nucleic acid hydrolysis activity. In addition, the catalytic domain can be engineered by in vitro selection to achieve high sequence recognition specificity, single base level reaction site specificity, customizability, stability and / or low cost. For example, the substrate domain comprises the sequence of SEQ ID NO:18. For example, the substrate domain comprises an A, C or G at the 3' end. For example, the 3' end of the substrate domain is an A, C or G. For example, the 3' end of the substrate domain is not T. On the one hand, the present application provides a nucleic acid comprising one or more catalytic domains and one or more substrate domains, wherein the catalytic domain comprises a 13PD catalytic domain sequence, the catalytic domain cleaves the substrate domain at the cleavage site, and the substrate domain comprises a base selected from A, C and G on the 3' side of the cleavage site. For example, the nucleic acid may further comprise one or more binding domains, and the binding domains are located on both sides of and / or within the catalytic domain and / or the substrate domain. For example, the nucleic acid comprises one or more binding domains A located on both sides of the catalytic domain, the nucleic acid comprises one or more binding domains B located on both sides of the substrate domain, and the binding domain A is capable of binding to the binding domain B. For example, the nucleic acid comprises a binding domain A-5 located at the 5' side of the catalytic domain and a binding domain A-3 located at the 3' side of the catalytic domain, the nucleic acid comprises a binding domain B-5 located at the 5' side of the substrate domain and a binding domain B-3 located at the 3' side of the substrate domain, and the binding domain A-5 is complementary to the binding domain B-3 and / or the binding domain A-3 is complementary to the binding domain B-5. For example, the 13PD includes 13PD1, 13PD2, 13PD3, 13PD4 and / or mutants thereof. For example, the catalytic domain comprises the sequence of SEQ ID NO: 17. For example, the catalytic domain comprises nucleic acid hydrolysis activity. For example, the substrate domain comprises the sequence of SEQ ID NO: 18. For example, the substrate domain comprises an A, C or G at the 3' end of the substrate domain. For example, the 3' end of the substrate domain is not T. In one aspect, the present application provides a vector comprising the system of the present application and / or the nucleic acid of the present application. In one aspect, the present application provides a cell comprising the system of the application, the nucleic acid of the application and / or the vector of the application. In one aspect, the present application provides a composition comprising the system of the application, the nucleic acid of the application, the vector of the application and / or the cell described in the application. In one aspect, the present application provides a kit comprising the system of the present application, the nucleic acid of the present application, the vector of the present application, the cell of the present application, and / or the composition of the present application. On the one hand, the present application provides a method for preparing a product, which includes providing the system of the present application, the nucleic acid of the present application, the vector of the present application, the cell of the present application, the composition of the present application and / or the kit of the present application. In one aspect, the present application provides a product prepared according to the method of the present application. For example, the product to be prepared may contain nucleic acid. For example, the product to be prepared may contain DNA, RNA and / or PNA. For example, the product can include nucleic acids. For example, the product can include at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, 40, or 45, 50, 100, 1000, 10000, 100000, or 1000000 nucleotides. For example, a k-mer can be a subchain of length k contained in a biological sequence. The AGAT sequence will have 4 monomers (A, G, A, and T), 3 2-mers (AG, GA, AT), 2 3-mers (AGA, GAT), and 1 4-mer (AGAT). In one aspect, the present application provides a combination comprising providing a composition comprising about 1 mM to 2 mM Zn 2+ and about 5mM to 20mM Mn 2+ conditions. For example, the combination may include providing a 2+ and about 5mM Mn 2+ conditions. For example, the composition may comprise about 1 mM Zn2+ and about 5mM Mn 2+ For example, the combination may include about 1 mM Zn 2+ and about 5mM Mn 2+ , and the pH of the combination may be about 6-8. For example, the combination may include about 1 mM Zn 2+ and about 5mM Mn 2+ , and the pH of the combination can be about 7. Further, in some examples, the temperature can include at least about 4°C, 10°C, 15°C, 20°C, 25°C, 30°C 32°C, 36°C, 37°C, 38°C, 40°C, 41°C, 42°C, 45°C, 50°C, 55°C, 60°C, 65°C, 70°C, 75°C, 80°C, 90°C, or 95°C or, about 4-90°C, 15-50°C, 20-40°C, 32°C-42°C, 36°C-42°C, 38°C-42°C, 41°C-42°C, 37°C-95°C, 37°C-60°C, or 40°C-60°C. Further, in some examples, the reaction time may include at least about 15 min (such as at least 15 min, 18 min, 20 min, 25 min, 30 min, 40 min, 60 min, 1.5 hr, 2 hr, 4 hr, 6 hr, 8 hr, 10 hr, 12 hr, 18 hr, or overnight or about 15 min-overnight, 20 min-overnight, 40 min-overnight, 2 hr-overnight, 20 min-18 hr, 40 min-18 hr, 2 hr-18 hr, 6 hr-18 hr, or 8 hr-12 hr about 20 min or 2 hr). In one aspect, the present application provides a method for preparing a product, the method comprising providing a combination of the present application and providing a 5' nucleic acid cutter and a 3' nucleic acid cutter. For example, the 5' nucleic acid cutter and the 3' nucleic acid cutter can be used in combination at the same time. For example, the 5' nucleic acid cutter and the 3' nucleic acid cutter can simultaneously cut each of themselves in the combination. For example, the 5' nucleic acid cutter may comprise DNase I capable of generating a 3' cleavage product. For example, the 5' nucleic acid cutter is located at the 5' side of the product. For example, the 5' nucleic acid cutter and the product are separated and / or conjugated. For example, the 5' nucleic acid cutter and the product are located on the same strand. For example, the 5' nucleic acid cutter may include 13PD and mutants thereof. For example, the 5' nucleic acid cutter may include 13PD1, 13PB2, I-R3 and mutants thereof. For example, the 3' nucleic acid cutter may comprise DNase II capable of generating a 5' cleavage product. For example, the 3' nucleic acid cutter is located at the 3' side of the product. For example, the 3' nucleic acid cutter and the product are separated and / or conjugated. For example, the 3' nucleic acid cutter and the product are located on the same nucleic acid. For example, the 3' nucleic acid cutter may comprise II-R1 and mutants thereof. For example, the 3' nucleic acid cutter may include II-R1a, II-R1b, II-R1c, II-R1d and mutants thereof. Further, the one or more 5' nucleic acid cutters and the one or more 3' nucleic acid cutters can be used in various ratios, such as at least 1:1, 1:2, 1:3, 1:4, 1:5 or 1:10, or about 1:1-1:5 or 1:1-1:2 or about 1:2 5' nucleic acid cutter to 3' nucleic acid cutter. In one aspect, the present application provides a product prepared according to the method of the present application. For example, the product may comprise a nucleic acid. On the one hand, the present application provides a method for nucleic acid detection, which includes providing the product of the present application. For example, the product of the present application can be used as a padlock probe (PLP). For example, PLP combined with rolling circle amplification (RCA) can produce high-density clonal amplified rolling circle products (RCP) in preserved tissues and cells for detection. For example, the methods of the present application are performed in vitro, ex vivo, in vivo and / or in living cells. In one aspect, the present application provides a sequencing method, which includes providing the product of the present application. For example, the product of the present application can be used as a long padlock or long adaptor single-stranded oligonucleotide (LASSO) probe. For example, the genomic information of a sample can be analyzed by targeted sequencing. For example, the methods of the present application are performed in vitro, ex vivo, in vivo and / or in living cells. In one aspect, the present application provides a genetic engineering method, which includes providing the product of the present application. For example, the product of the present application can be used as an HDR template. For example, sequence insertion can use an exogenous DNA donor as a template for homology-directed repair (HDR). For example, the methods of the present application are performed in vitro, ex vivo, in vivo and / or in living cells. In one aspect, the present application provides a data storage method, which includes providing a product of the present application. For example, the products of the present application can be used for DNA and / or RNA based storage. For example, the methods of the present application are performed in vitro, ex vivo, in vivo and / or in living cells. Example The following examples are set forth in order to provide one of ordinary skill in the art with a complete disclosure and description of how to make and use the invention and are not intended to limit the scope of what the inventors believe to be their invention nor to represent that the experiments below are all or the only experiments performed. Efforts have been made to ensure the accuracy of the numbers used (e.g., amounts, temperatures, etc.), but certain experimental errors and deviations should be taken into account. Unless otherwise indicated, parts are parts by weight, molecular weight is weight average molecular weight, temperature is in degrees Celsius, and pressure is at or near atmospheric pressure. Standard abbreviations may be used, such as bp: one or more base pairs; kb: one thousand or thousands of bases; pl: one or several picoliters; s or sec: one or several seconds; min: one or several minutes; h or hr: one or several hours; aa: one or more amino acids; nt: one or more nucleotides; im: intramuscular (intramuscular); ip: intraperitoneal (intraperitoneal); sc: subcutaneous (intramuscular); and the like. method Reselect II-R1 for 3' self-cleavage. Based on the II-R1 sequence, we synthesized several degenerate DNA libraries (IDT), including 5′-pGAGTGCTACGAACGTAGG AGCATCTTTGGCGT ACAAGCGAAGCTTGT ACGCTAGGGGAATAAAT CTTTGGGTGC CTACGTTCGTAGGACTC,(SEQ ID NO:1) 5′-pGAGTGCTACGAACGTAGA AGCATCTTTGGCGT ACAAGCGAAGCTTGT ACGCTAGGGGAATAAAT CTTTGGGTGT CTACGTTCGTAGGACTC,(SEQ ID NO:2) 5′-pGAGTGCTACGAACGTAGT AGCATCTTTGGCGT ACAAGCGAAGCTTGT ACGCTAGGGGAATAAAT CTTTGGGTGA CTACGTTCGTAGGACTC,(SEQ ID NO:3) 5′-pGAGTGCTACGAACGTAGC AGCATCTTTGGCGT ACAAGCGAAGCTTGT ACGCTAGGGGAATAAAT CTTTGGGTGG CTACGTTCGTAGGACTC,(SEQ ID NO:4) and (5′-pGAGTGCTACGAACGT AGGAGCATCTTTGGCGT ACAAGCGAAGCTTGT ACGCTAGGGGAATAAA TCTTTGGGTGCCTACGTTCGTAGGACTC), (SEQ ID NO:1) The degeneracy of each underlined nucleotide (41-46 nt in total) was 0.18. This generated an initial (G0) DNA pool containing DNA molecules that had an average of 7 to 8 mutations relative to the complete II-R1 precursor. We also designed a pair of primers 1 (5′-pGAGTGCTACGAACGT (SEQ ID NO: 5)) and 2 (5′-AAAAAAAAAAAAAAA (SEQ ID NO:6) / spacerC18 / GAGTCCTACGAACGT (SEQ ID NO:7)) For selective amplification. Primer 2 contains a spacer modification (spacerC18) to block the polymerase from 15 The extension on the tail allows the sense and antisense strands of the PCR product to be distinguished by length by dPAGE. For each library, to start reselection, we ligated 200 pmol of the G0 population with CircLigase (200 units, EpiCentre) at 60°C for 2 hours in a 200 μL mixture containing 1X CircLigase reaction buffer, 50 μM ATP, and 2.5 mM MnCl2. We precipitated the reaction products with 100% ethanol and purified the monomeric DNA circles using 10% dPAGE. We then incubated the recovered circular DNA at 37°C for 30 minutes in 100 μL selection buffer containing 50 mM HEPES (pH 7.0 at 23°C), 100 mM NaCl, 10 mM MgCl2, and 2 mM ZnCl2. We separated the cleaved DNA (linear) from the uncleaved DNA (circular) by 10% dPAGE. The recovered linear DNA was religated with CircLigase (30 units, EpiCentre) in a 30 μL mixture containing 1X CircLigase reaction buffer, 50 μM ATP and 2.5 mM MnCl2. We then separated the circular DNA by 10% dPAGE. Using them as templates, we performed PCR amplification with 100 pmol each of primers 1 and 2. Based on the length difference, we separated the sense strand (91 nt) from the antisense strand (106 nt) of the PCR product on 10% dPAGE. We recovered the sense DNA to reconstruct the DNA pool for the next round of selection. To select II-R1 mutants with robust activity in cleaving DNA, we shortened the incubation time of the DNA pool with selection buffer from 30 min (G0-G3) to 5 min (G4-G5) and then to 1 min (G6-G7). We selected the G3 pool and deep sequenced it using NGS. Based on the G3 sequencing data of the five libraries, we reconstructed the class II Zn 2+ Consensus sequence and secondary structure model of dependent DNAzymes. In addition, we collected ~ 100 clones from G7 (TOPO TA cloning kit, Invitrogen) and sequenced them separately. This produced 38 unique sequences, which were screened to identify mutants of II-R1 (II-R2-G, II-R2-A, II-R2-C and II-R3) that had the desired activity and sequence universality at 5' of the cleavage site (four mutants were used in combination to achieve universality). DNA enzyme cleavage assay. We designed DNA enzymes in either single or double molecular form for cleavage assay. DNA enzymes were incubated in the corresponding reaction buffer, i.e., 50 mM HEPES (pH 7.0 at 23°C), 100 mM NaCl, 10 mM MgCl2, 20 mM MnCl2, and 1 mM ZnCl2 for 13PD1 and its variants, and 50 mM HEPES (pH 7.0 at 23°C), 100 mM NaCl, 10 mM MgCl2, and 2 mM ZnCl2 for II-R1, II-R2, and II-R3. Incubation was performed at 37°C for several minutes to several hours, depending on the purpose of the assay. To map the cleavage site of the DNA enzyme, the sample was incubated for 1 hour and then mixed with (v / v: 1 / 1) loading buffer (90% formamide, 30 mM EDTA, 0.025% bromophenol blue, 0.025% xylene cyanol) to stop the reaction. To characterize the kinetics of DNase, samples were pipetted and mixed with (v / v: 1 / 1) loading buffer to stop the reaction at different time points (0 sec, 20 sec, 40 sec, 1 min, 2 min, 5 min, 10 min, 20 min, 40 min, and 1 h). We then used denaturing PAGE to analyze the cleavage. For kinetic assays on bimolecular constructs, we labeled the substrate DNA strand with 5′ FAM and detected the fluorescence signal on the dPAGE gel using a Typhoon FLA9500 scanner. We extracted the time relationship of the cleavage fractions from the gel to calculate the k of each DNA enzyme. obs and yield. Use the following formula to establish k obs Value: Cutting part = FC max (1-e -kt ), where k = k obsAnd FC max = Maximum of the cut portion. For mapping assays, we stained the gels with SYBR Gold, scanned them with a Bio-rad ChemiDoc MP imaging system, and analyzed the data using ImageQuant software. PECAN solution. Design of custom ssDNA pseudogenes. We initiated the protocol by designing a DNA construct that carries a pair of self-cleaving DNA enzymes at the 5′ and 3′ ends of the custom ssDNA for phagemid recombination. The nucleotide identities at the 5′ and 3′ ends of the custom sequence determine the corresponding DNA enzymes selected. The rule for the 5′ DNA enzyme is 13PD1 for 5′T, 13PD1-A for 5′A, 13PD1-G for 5′G, and 13PD1-C for 5′C. The bold base parts are the catalytic domain and substrate domain, and the sequences are conserved; The underlined bases are the base-pairing regions, and the order can be changed; Label | Italic bases are cleavage sites (1) The catalytic domain and substrate domain of the DNA enzyme are separated and function as two DNA strands: 13PD1 catalytic sequence: 5' GTCGCCATCTCTTC TATACCGGGCAACTATTGCCTCGTCATCGCTATTTTCTGCG ATAGTGAGTCGTATTA -3' (SEQ ID NO:8) 13PD1 substrate sequence: 5'- TAATACGACTCACTAT ACTGC|T GAAGAGATGGCGAC -3' (SEQ ID NO:9) 13PD1-A catalytic sequence: 5' GTCGCCATCTCTTC TATACCGGGCAACTATTGCCTCGTCATCGCTATTTTCTGCG ATAGTGAGTCGTATTA -3' (SEQ ID NO:8) 13PD1-A substrate sequence: 5'- TAATACGACTCACTAT ACTGC|A GAAGAGATGGCGAC -3' (SEQ ID NO: 10) 13PD1-C catalytic sequence: 5' GTCGCCATCTCTTC TATACCGGGCAACTATTGCCTCGTCATCGCTATTTTCTGCG ATAGTGAGTCGTATTA-3' (SEQ ID NO:8) 13PD1-C substrate sequence: 5'- TAATACGACTCACTAT ACTGC|C GAAGAGATGGCGAC -3' (SEQ ID NO: 11) 13PD1-G catalytic sequence: 5' GTCGCCATCTCTTC TATACCGGGCAACTATTGCCTCGTCATCGCTATTTTCTGCG ATAGTGAGTCGTATTA -3' (SEQ ID NO:8) 13PD1-G substrate sequence: 5'- TAATACGACTCACTAT ACTGC|G GAAGAGATGGCGAC -3' (SEQ ID NO: 12) (2) The catalytic domain and substrate domain of the DNA enzyme are located on one DNA chain and function as one DNA chain: 13PD1: 5' GTCGCCATCTCTTC TATACCGGGCAACTATTGCCTCGTCATCGCTATTTTCTGC G ATAGTGAGTC GTATTA TTT TAATACGACTCACTAT ACTGC|T GAAGAGATGGCGAC -3' (SEQ ID NO: 13) 13PD1-A: 5' GTCGCCATCTCTTC TATACCGGGCAACTATTGCCTCGTCATCGCTATTTTCTGC G ATAGTGAGTC GTATTA TTT TAATACGACTCACTAT ACTGC|A GAAGAGATGGCGAC -3' (SEQ ID NO: 14) 13PD1-C: 5' GTCGCCATCTCTTC TATACCGGGCAACTATTGCCTCGTCATCGCTATTTTCTGC G ATAGTGAGTC GTATTA TTT TAATACGACTCACTAT ACTGC|C GAAGAGATGGCGAC -3' (SEQ ID NO: 15) 13PD1-G: 5' GTCGCCATCTCTTC TATACCGGGCAACTATTGCCTCGTCATCGCTATTTTCTGC G ATAGTGAGTC GTATTATTT TAATACGACTCACTAT ACTGC|G GAAGAGATGGCGAC -3' (SEQ ID NO: 16) The choices for 3' DNA enzymes are II-R2-G for 3'G, II-R2-A for 3'A, II-R3 for 3'T, and II-R2-C for 3'C. Once the DNA enzyme pairs are determined, we complement their sequences to both ends of the custom ssDNA so that the complements can self-fold into the secondary structure of the corresponding DNA enzyme by recruiting the terminal sequence of the custom ssDNA as part of its structure. This is achieved by programming the complementary sequence of ~15 nt to complement the terminal sequence of ~15 nt of the custom ssDNA, thereby forming the key support stem of the DNA enzyme (see Examples and detailed information). Fig.11 ). Supplementation of the DNA enzyme sequence extends the length of the custom DNA to more than 200 nt. We regard such long DNA constructs as double-stranded pseudogene fragments for gene synthesis. Synthesis of custom ssDNA pseudogenes. In this study, we designed pseudogenes ranging in length from ∼230 bp to ∼7000 bp. Such large DNA fragments can be efficiently assembled in yeast by assembling a series of overlapping synthetic ssDNAs (∼100-150 nt in length) with a linearized plasmid vector in a single step in a simple transformation event (Gibson assembly). 26 This technology has been commercialized by many companies to synthesize "gene fragments". In this paper, we asked a local company (Shanghai Jierui Bioengineering Co., Ltd.) to assemble our pseudogene fragments with the p3024 phagemid vector (rather than a common plasmid vector) during the transformation process. The product was delivered to us in the form of recombinant p3024 phagemid (~5μg) with the pseudogene inserted. Afterwards, the recombinant p3024 can be used to produce phagemid particles carrying ssDNA phagemids with the help of helper phages. Production of ssDNA phagemid particles. For each phagemid amplification, we thawed 100 μL of JM109 competent cells (Shanghai Bioengineering Co., Ltd.) on ice and mixed the cells with 1-10 ng of recombinant p3024 phagemid and incubated on ice for 30 minutes. Then, we heat pulsed the sample in a 42°C water bath for 45 seconds and incubated it on ice again for 2-3 minutes. We added 900 μL LB culture medium to the sample and vibrated it at 220 r / min for 1 hour at 37°C. Then, the sample was centrifuged at 5000 r / min for 5 minutes. We removed 900 μL of supernatant, resuspended the cells in the remaining culture medium, and plated the culture medium on a preheated (37°C) LB agar plate containing ampicillin (100 μg / ml). We inverted the plate and incubated it at 37°C for 12 hours. The next day, we picked single colonies (usually 2 to 4) and screened the colonies with correctly transformed recombinant p3024 by sequencing. For a typical culture, we grew a single colony of the recombinant p3024 transformation overnight at 37°C in 15 mL LB medium containing ampicillin (100 μg / ml). We then inoculated 3 ml of the overnight culture into each of four 300 ml bottles of 2x YT medium (16.0 g / l tryptone, 10.0 g / l yeast extract, 5.0 g / l NaCl, 5 mM MgCl2, pH 7.0) and shook them at 37°C at 250 r / min. We monitored the OD of the culture every 30 minutes. 600 When OD 600 When the value reached ∼0.4-0.5, we added VCSM13 helper phage to an MOI of 20 (phage to cell ratio, 50 μL of 3 x 10 10 phage / μL OD of VCSM13 phage stock solution and 300ml cell culture 600 The value is ~0.5 (2.5x 10 8Cells / ml)) in the culture. After 30 minutes, we added kanamycin (final concentration of 70 μg / ml) to the culture to select infected cells. We continued to shake the culture for 4.5 hours, then collected the culture and centrifuged it at 4°C for 15 minutes at 4000r / min. We transferred the supernatant to a clean bottle and supplemented it with PEG 8000 (40g / l) and sodium chloride (30g / l). After vigorous agitation (stirring) to dissolve the powder, we incubated the mixture on ice for 30 minutes, then centrifuged it at 4°C for 30 minutes at 5000rcf. We discarded the supernatant and resuspended the phagemid pellet in 10ml Tris (10mM, pH 8.5), which was further centrifuged at 4°C for 10 minutes at 16000rcf to remove any bacterial residues. We collected the resulting supernatant containing pure recombinant p3024 phagemid particles. Extraction of ssDNA phagemids. ssDNA phagemids were extracted from phagemid particles by stripping off the protein capsid. We mixed 2 volumes (relative to the volume of the phagemid particle collection) of NaOH (0.2 M, containing 1% SDS) with the phagemid collection by vortexing. We incubated the mixture at room temperature for 3 minutes, and then gently mixed 1.5 volumes of KOAc (3 M, titrated to pH 5.5 with glacial acetic acid) with the sample by inversion. We then further incubated the sample in an ice-water bath for 10 minutes and centrifuged at 16000 rcf for 30 minutes at 4°C. We collected the supernatant, mixed it with 2 volumes of 100% ethanol, and incubated it in an ice-water bath for 30 minutes. We spun the mixture again at 16000 rcf for 30 minutes at 4°C, collected the precipitate (recombinant p3024 ssDNA), and washed it with 75% ethanol to remove other salts. We air-dry the pellet for 10 minutes and then freeze-dried it for weighing and storage. Typically, we obtain 3-8 mg of recombinant p3024 ssDNA from 1.2 L of culture prepared in shake flasks. When we culture in 10 L laboratory fermenters, we routinely obtain 0.4-1 g of recombinant p3024 ssDNA. Release of customized ssDNA by inducing DNA enzyme cleavage. Customized ssDNA was amplified via the p3024 vector. To release it from the vector, we induced self-cleavage of the programmed DNA enzymes located on both sides of the customized ssDNA. We dissolved the recombinant p3024 ssDNA (final concentration of 100 nM) in a buffer containing 50 mM HEPES (pH 7.0 at 22°C), 100 mM NaCl, and 10 mM MgCl2. Then, we performed an annealing protocol of 90°C for 3 min, 75°C for 5 min, 60°C for 5 min, 45°C for 5 min, and 22°C for 5 min. We added an equal volume of a second buffer containing 50 mM HEPES (pH 7.0 at 23°C), 100 mM NaCl, 10 mM MgCl2, 10 mM MnCl2, and 2 mM ZnCl2 to the sample and incubated at 37°C for DNA enzyme-catalyzed DNA treatment for several hours (2-4 h). We vigorously mixed the reaction product with 3 volumes of 100% ethanol (precooled at 4°C) and centrifuged the mixture at 16000 rcf at 4°C for 30 minutes. We collected the precipitate, washed it with 75% ethanol (precooled at 4°C) to remove residual salts, centrifuged the sample again at 16000rcf for 7 minutes at 4°C, and then resuspended the precipitate in 1× denaturing loading buffer (40mM Tris, 40mM borate, 6M urea, 0.5mM EDTA, pH 7.2, 10% (w / v) sucrose, 0.05% SDS, 0.01% (w / v) bromophenol blue, 0.01% (w / v) xylene cyanol). For custom ssDNA with a length of less than 1000nt, we chose denaturing PAGE to purify it; for custom ssDNA with a length of more than 1000nt, we purified it by denaturing agarose gel (see example Fig.12 ). Alternatively, we used an anion exchange chromatography protocol for large-scale (mg-g) purification of ssDNA. RNA in situ detection. For cell samples grown on slides, we used 0.1M HCl to permeabilize the cells. Then, the samples were washed for 2 minutes with 0.05% (v / v) Tween-20 in 1× diethylpyrocarbonate-treated phosphate buffered saline (DEPC-PBS). For formalin-fixed paraffin-embedded (FFPE) tissue sections of human breast cancer obtained from the Department of Pathology, Quanzhou First Hospital, Fujian Medical University, China, we incubated them in an oven at 60°C for 30 minutes and then washed them twice in succession with ddH2O, once for 15 minutes and once for 10 minutes. The slides were rehydrated twice with a series of decreasing concentrations of ethanol (100%, 95%, 70%) for 2 minutes each, treated with diethylpyrocarbonate-treated H2O (DEPC-H2O) for 5 minutes and 1×DEPC-PBS for 2 minutes, followed by fixation with 4% paraformaldehyde for 10 minutes. The samples were washed for 2 minutes with 1×DEPC-PBS. Permeabilization was performed in 0.1 M HCl solution containing 0.1 mg / ml pepsin at 37°C for 30 min. Dehydration was then performed in a gradient of 70%, 85%, and 100% ethanol for 1 min each. The use of human tissue materials complied with the requirements of the Ethics Committee of Huaqiao University. After pretreatment, the reaction zone was delineated using a safe seal hybridization chamber (Thermo Scientific) or an ImmEdge pen (Sigma-Aldrich). We added 0.1 μM padlock probes (chemically synthesized with 5′ phosphorylation or prepared from PECAN) in hybridization buffer (6× saline sodium citrate (SSC, Sigma-Aldrich), 10% formamide) to the reaction zone and incubated at 37°C for 2 h. Then, the samples were washed three times with 2× SSC supplemented with 20% formamide and three times with DEPC-PBS. Next, we incubated the samples at 37°C for 1 h with a reaction mixture containing 0.5 U / μL SplintR ligase, 1× SplintR ligase reaction buffer (New England Biolabs), 50% (v / v) glycerol, 1 U / μL RiboLock RNase inhibitor, and 0.2 μg / μL BSA in DEPC-H2O. After washing three times with DEPC-PBS, we added 1 μM primer DNA in rolling circle amplification (RCA) buffer to the samples and incubated at 37°C for 30 minutes, followed by three washes with DEPC-PBS. Then, RCA reactions were performed overnight at 30°C in a mixture of 1U / μL phi29 DNA polymerase, 1× phi29 DNA polymerase reaction buffer, 1mM dNTPs, 5% (v / v) glycerol, and 0.2μg / μL BSA in DEPC-H2O. The samples were washed three times with a mixture of 1× DEPC-PBS, 2× SSC, and 20% formamide. Afterwards, we applied 0.1 μM detection probe to the samples and kept them at 22°C for 30 minutes. Excess probe was removed by washing three times with DEPC-PBS. Then, samples were stained with 0.5μg / mL DAPI in SlowFade Gold antifade mounting medium (Thermofisher) before imaging. To analyze images captured by fluorescence microscopy, we used Ilastik (https: / / www.ilastik.org) to identify cell nuclei and CellProfiler (https: / / www.cellprofiler.org / ) to identify RCP spots. RNA splicing analysis. Design and construction of LASSO probes. Based on known transcript information, we selected appropriate sites (25-35 nt) on the transcripts of interest to set the length of the captured sequence in the transcript to ~400-800 nt to span two to three exons for specific recognition by LASSO probes. Then, by filling ~300-500 scrambled nucleotides between a pair of primers that bind to the recognition site as long adaptors, the pair of primers was covalently linked in the manner of an inverted molecular probe. The resulting LASSO probe was subjected to the PECAN protocol to generate ssDNA. cDNA preparation. We used TRIzol reagent (Invitrogen) from ~10 μg of each sample according to the attached user guide. 7 Total RNA was isolated from 10 cells. To synthesize cDNA, we used a commercial kit (PrimeScript TM The cDNA was quantified by NanoDrop spectrophotometer (Thermo Scientific). Capture by LASSO probe. We mixed 1-10fmol of LASSO probe with 100ng cDNA in 20μL 1× amplification buffer (EpiCentre). To ensure the hybridization of LASSO probe with cDNA, we heated the mixture to 98°C for 5 minutes and slowly cooled to 56°C at a rate of 1°C per minute. For probe extension and ligation, 0.6U Phusion polymerase, 5U amplification enzyme (EpiCentre) and 3pmold NTP were added to the mixture. The sample was further incubated at 56°C for 60 minutes, 72°C for 20 minutes, 95°C for 3 minutes, and then cooled on ice. In order to eliminate linear cDNA in the mixture, we digested the reaction product with 0.5μL exonuclease I (20 units / μL) and 0.5μL exonuclease III (100 units / μL) at 37°C for 30 minutes. Afterwards, the exonuclease in the sample was inactivated by incubating at 90°C for 10 minutes. Detection and sequencing of captured products. For each captured product, we used a pair of primers targeting the probe adapter region to amplify the captured sequence (see Figure 3 b) About 5 μL of the captured product was used as an amplification template and 30 PCR cycles were performed. The PCR product was analyzed by agarose gel electrophoresis and sequenced after gel purification. Gene knock-in. Cell culture. HEK 293T cells were maintained in DMEM (Hyclone) glutamax medium supplemented with 10% fetal bovine serum (FBS, Gibco), 100 units / ml penicillin and 100 g / ml streptomycin (Beyotime). H9 hESCs were cultured on matrigel-coated plates (Gibco) in mTeSRTM basal medium (Stemcell Technologies) with 10% FBS. All cells were stored in a humidified atmosphere of 5% CO2 at 37°C. In vitro transcription and purification of sgRNA. The DNA template for sgRNA was purchased from Shanghai Jierui Biotechnology (China) Co., Ltd. Transcription was performed in 1× transcription buffer (40mM Tris pH 8.0, 20mM MgCl2, 5mM DTT, and 2mM spermidine) supplemented with 2mM NTP, 80pmol DNA template, and 10U T7 RNA polymerase. The sample was incubated at 37°C for 3 hours. The sgRNA product was then purified with 8% denaturing PAGE gel, aliquoted and stored at -80°C. Expression and purification of Cas9. Recombinant Streptococcus pyogenes (S. pyogenes) Cas9 (pMJ915) construct was purchased from Addgene (plasmid number: 69090) and transformed into E. coli BL21 (DE3) competent cells for Cas9 expression. Single colonies transformed with pMJ915 were grown in 10 ml LB medium containing 100 μg / ml ampicillin at 37°C and shaken at 250 rpm overnight. Then, the cells were inoculated into 1 l 2×YT medium and cultured at 37°C until OD 600Reach ~ 0.4-0.5. The culture was cooled to 15°C and incubated for 2 hours. Protein expression was induced by 0.1mM isopropyl β-D-1-thiogalactopyranoside (IPTG) supplement. After 16 hours of cultivation at 15°C, cells were precipitated by centrifugation at 5000rpm for 15 minutes at 4°C. After removing the supernatant, the cells were resuspended in 300mM NaCl, 30mM Tris-HCl (pH8.0) and 0.01% β-mercaptoethanol lysis buffer and lysed using a high pressure homogenizer (EmulsiFlex-C3, Avestin). Cell lysates were collected and centrifuged at 16000rpm for 30 minutes at 4°C. Then, the collected supernatant was incubated with Ni Agarose TM 6 fast flow beads (GE Healthcare) at 4°C for 1 hour. We use a buffer containing 500mM NaCl, 30mMTris-HCl (pH 8.0), 0.01% β-mercaptoethanol and 40mM imidazole to wash the beads and remove non-specifically bound proteins. After washing, the Cas9 protein was eluted with a buffer of 150mM NaCl, 30mM Tris-HCl (pH 8.0), 0.01% β-mercaptoethanol and 220mM imidazole. The eluate was further purified using SS5 (AKTA purification system, GE Healthcare) cation exchange chromatography. The resulting Cas9 protein was quantified using a BCA protein assay kit (Abcam) and stored at -80°C in a buffer of 25mM HEPES (pH 7.4), 30mM NaCl, 3mM DTT and 20% glycerol. Preparation of dsDNA HDRT. All dsDNA HDRTs were prepared by PCR amplification using the corresponding plasmid as a template (sequences are shown in Supplementary Tables 1 and 2). Amplification was performed in a 50 μL solution mixed with 25 μL 2× Phanta Flash Master Mix (Novozymes Biotech), 2 μL of each primer (10 μM), 1 μL of plasmid template (10 ng / μL) and 20 μL ddH2O. The product was purified using TaKaRa MiniBEST DNA Fragment Purification Kit Version 4.0 (Takara Biotech Co., Ltd.). The DNA samples were resuspended in ddH2O and quality checked by 1% agarose gel electrophoresis. The concentration of each dsDNA HDRT was determined by Nanodrop (ThermoFisher). Supplementary Table 1 Supplementary Table 2 name Sequence (5' to 3') mEGFP-TUBA1B HDRT (1,570nt) SEQ ID NO:27 FBL-mEGFP HDRT (1,480nt) SEQ ID NO:28 CLTA-mCherry HDRT (1,390 nt) SEQ ID NO:29 RAB11A-BFP HDRT (1,355 nt) SEQ ID NO:30 ssDNA HDRT was prepared by exonuclease digestion (Kit). We used the same protocol in the preparation of dsDNA HDRT to first obtain dsDNA HDRT. During PCR amplification, we used 5′ phosphorylated primers to generate dsDNA so that one of the strands could be digested afterwards. According to the manufacturer's recommendations, we used Guide-it TM Long Purified dsDNA HDRTs were processed with the ssDNA Production System (Takara Biotechnology Co., Ltd.). Specifically, the DNA strand with a 5' phosphate was digested by Strandase Mix A&B. After enzyme digestion, the remaining ssDNA product was purified using the NucleoSpin Gel and PCR Cleanup Kit (Macherey-Nagel). Using this strategy, we prepared sense and antisense ssDNA HDRTs. The ssDNA samples were quality checked by 1% agarose gel electrophoresis. The concentration of each ssDNA HDRT was quantified by Nanodrop. Cell electroporation. HEK 293T cells and H9 hESCs cells were transfected using the Neon Transfection System 10 μL Kit (Thermo Fisher) according to the manufacturer's recommendations. For each homologous recombination assay, 1.5 μg of Cas9 protein and 360 ng of sgRNA were added to resuspension buffer R in a final volume of 2 μL. The samples were incubated at 23 °C for 10 min to allow pre-assembly of Cas9 RNPs. 2.5 μg of HDR donor DNA (dsDNA / PECAN ssDNA or Kit ssDNA) was dissolved in 8 μL of buffer R and then supplemented with RNPs. A total of 10 μL of sample was mixed with 1.8 × 10 5 HEK 293T cells or 5 × 10 5 Mix 2 μL of Buffer R with 100 μL of H9 hESCs. Immediately electroporate the cells using the optimized program. For HEK 293T cells, set the program to 1200V, 2 pulses, and a pulse width of 20 ms. After electroporation, seed HEK 293T cells in 500 μL of pre-warmed DMEM medium in a 24-well plate. For H9 hESCs, first use Accutase TM (Gibco) to dissociate cells into single cell suspension. The subsequent electrophoresis program was set to 1100V, 2 pulses, and a pulse width of 20ms. After electrotransfection, H9 hESCs cells were seeded in 500μL pre-warmed mTeSRTM Plus medium on Matrigel-coated 24-well plates. The electroporated cells were cultured for 2-3 days and then dissociated into single cells for FACS analysis. Flow cytometry and analysis. To determine the percentage of mEGFP-positive, mCherry-positive, or mBFP-positive cells, HEK 293T cells and H9 hESC cells were analyzed individually on a BD LSRFortessa flow cytometer after electroporation and culture. Cell sorting was performed on a Moflo Astrios EQ 4. Flow cytometry data were analyzed and graphs were prepared using FlowJo software (FlowJo LLC). Cell imaging. For confocal microscopy imaging, HEK 293T cells and H9hESCs were grown individually in 35 mm glass culture dishes (Cellvis) after electroporation or cell sorting. Live cells were imaged on a TCS SP8 STED 3X microscope (Leica) at 63× and 63×3 magnifications. Example 1 DNA enzyme is used for PECAN development. Despite numerous efforts in selection and optimization, the lack of broad sequence universality remains an unsolved problem for DNA enzyme-guided DNA-specific cleavage. With this in mind, we conceived PECAN in a way that circumvents rather than overcomes this universality problem. By programming different DNA enzymes 1 and 2 as 5′ and 3′ self-cleavage scissors of target oligonucleotides, respectively, we anticipated that the stringency required for sequence universality for each enzyme to be used for scarless oligonucleotide production would be reduced ( Figure 1 a). It is conceivable that with such a scheme we would only need a DNAzyme 1 that tolerates the 3' sequence and a DNAzyme 2 that tolerates the 5' sequence at its corresponding cleavage site. By searching the pool of known DNA-cleaving DNA enzymes, we quickly identified 13PD1 and I-R3 as potential candidates for DNA enzyme 1, as both have been reported to perform site-specific hydrolysis of DNA and have only one (for 13PD1, Figure 1 b) or two (for I-R3, Figure 6 a) Conserved nucleotides (nt). The robustness of both enzymes at 37°C is reflected by the observed rate constants (k obs ) value is ~1min -1 And the yield was >90% within 5 minutes. Point mutation experiments confirmed the preference for ^T>A>G>C-3′ for 13PD1, such as k obs The 10-fold reduction from ^T to ^C is shown in ( Figure 1 However, such loss of catalytic speed can be easily compensated by a modest extension of the reaction time (e.g., from 5 min to 1 h) to achieve almost uncompromised yields (>85%) in DNA cleavage of the ^A, ^G, or ^C mutants of 13PD1 ( Figure 1In contrast, I-R3 showed poor sequence tolerance at the conserved ^AG-3′ position, with most mutants showing irreparable cleavage yields ( Figure 6 bd). According to the reported secondary structure model of the enzyme ( Figure 1 b), the nucleotides downstream of ^T-3′ in 13PD1 are buried in the apparent stem. In general, they can be programmed to any identity as long as the base complementarity in the stem is maintained. Comprehensive covariation of the first base pair downstream of ^T-3′ consistently revealed that the yields of 13PD1 and ^A, ^G, ^C mutants were unchanged (>85% within 1 hour) ( Figure 7 ). Overall, we determined that 13PD1 can be used as a DNase 1 to efficiently generate 3' cleavage products with customizable 5' ends (^NN-3', N refers to any nucleotide). Next, we turned to DNase 2 and considered II-R1 as a candidate because II-R1 hydrolyzes DNA immediately after the 5' stem ( Figure 1 c). However, testing showed that the enzyme also has nucleotide preferences (5′-G>A / T / C^), and even for the preferred 5′-G^, II-R1 only obs The value is 0.013min -1 Or cleavage with 60% yield in 1 hour ( Figure 1 f, Figure 8 a). In order to improve both the 5′ sequence tolerance and hydrolytic activity of II-R1, we preset the 5′ nucleotide to G, A, T, or C and created corresponding degenerate DNA libraries to reselect mutants that can cleave faster (see Methods, Figure 8 b). Post-reselection analysis revealed a mutant named II-R2, which had a 1-hour cleavage yield of more than 85% for 5′-G / A / C^, but an insufficient 1-hour yield for 5′-T^ (63%), and a second mutant named II-R3, which had a 1-hour yield of ∼88% for 5′-T^ ( Figure 1 cd and f, Figure 8 c and Fig. 9 a). Comprehensive covariation experiments confirmed that for II-R2, the nucleotides in the upstream stem of 5′-G / A / C^ are programmable, and for II-R3, the nucleotides in the upstream stem of 5′-T^ are programmable ( Fig. 9 Thus, the combined use of II-R2 and II-R3 as DNase 2 can robustly generate 5′ cleavage products with customizable 3′ ends (5′-NN^). Therefore, pairing II-R2 / 3 with 13PD1 for double cleavage should generate DNA fragments with customized 5′ to 3′ sequences (5′-NN...NN-3′) ( Figure 1 a). Considering the different metal ion dependencies of these enzymes, we identified a compatible buffer condition (50 mM HEPES, pH 7.0, 1 mM Zn 2+ and 5 mM Mn 2+ ), each of which can self-cleave more than 85% of the DNA within 2 hours at 37°C ( Fig.10 ), which allows for simultaneous cleavage of both enzymes in a one-pot reaction. Based on these findings, we were able to program a pair of correct DNA enzymes 1 and 2 to flank any sequence of a target oligonucleotide ( Fig.11 ), synthesized as a pseudogene fragment, and amplified via a p3024 phagemid vector (pBluescript variant) to generate the PECAN oligonucleotide (see Methods, Figure 1 a) Note that because this pair of DNA enzymes precisely cleaves the 3' phosphate bond, the PECAN oligonucleotide naturally has a 5' phosphate and a 3' hydroxyl terminus. Example 2 Length, quantity, purity and sequence customizability of PECAN oligonucleotides. Recombinant phage carrying very long DNA inserts are prone to produce fragmented byproducts during in vivo replication. Our experiments revealed that recombinant p3024 can be efficiently amplified in Escherichia coli with inserts <7000 base pairs (bp), consistently producing single-stranded phagemids without byproducts. Using shake flask cultures, we routinely harvested several milligrams of single-stranded phagemids. Using a 10-L laboratory fermenter ( Fig.12 a), further increasing the quantity to the gram level, consistent with previous reports on phage production. In the post-amplification automated process, the paired use of II-R2 / 3 and 13PD1 showed robust results in excising a range of oligonucleotide lengths (ranging from ∼70mer to 6750mer), with a yield of >85% ( Fig.12 b). PECAN recruits bacterial replication machinery and autocatalytic DNA enzymes to efficiently generate DNA oligonucleotides on a large scale. The high fidelity of the former and the high specificity of the latter should also guarantee the purity of the oligonucleotide products in principle. To test this, we compared PECAN with oligonucleotides generated by chemical synthesis (CS) ( Figure 2ad). The selected representatives include 65mer, 69mer and 71mer, with GC contents of 74%, 51% and 46%, respectively. When subjected to denaturing polyacrylamide gel electrophoresis (dPAGE), the three PECAN oligonucleotides all showed clean and clear bands on the gel, while the CS oligonucleotides (purified by PAGE) all produced fuzzy bands, indicating that the latter had non-negligible impurities ( Figure 2 a and c). These results are consistent with the data from monoisotopic (accurate mass) spectroscopy, where PECAN 71mer shows a single mass peak for the full-length oligonucleotide, while CS 71mer has many peaks around the main full-length oligonucleotide ( Figure 2 b). Using next-generation sequencing (NGS), we thoroughly analyzed the composition of these samples. For CS, as the length increased from 65mer to 71mer, the proportion of error-free full-length oligonucleotides decreased from 64.1% to 49.7%, while the full-length purity of the 69mer telomeric sequence decreased significantly by only 6.1%, which may be due to the presence of a strong secondary structure of G-quadruplex (G4) ( Figure 2 d) Among the errors in CS oligonucleotides, single-base indels (insertions or deletions) and mutations accounted for the majority and occurred more frequently at the ends of the oligonucleotides ( Fig.13 ). In contrast, in PECAN 65mer and 71mer molecules, error-free full-length oligonucleotides accounted for >98%, regardless of their length and GC content differences. Even for the highly error-prone 69mer G4 sequence, PECAN ensured >90% purity ( Figure 2 d). Therefore, PECAN can achieve single-base accuracy in oligonucleotide production. In addition to these three representatives, we successfully produced PECAN with different sequence identities, especially at the termini ( Fig.14 )) and have different sequence lengths (from tens to hundreds to thousands of nucleotides ( Figure 3 c, Various DNA oligonucleotides of 4a), which demonstrates the good customizability of PECAN. Application of Example 3 in in situ detection of RNA. 60-100mer DNA oligonucleotides can be designed as padlock probes (PLPs) widely used in single-molecule fluorescence in situ hybridization, a powerful technique for studying gene expression in single cells. Combined with rolling circle amplification (RCA), PLP can generate high-density clonal amplification rolling circle products (RCPs) in preserved tissues and cells for in situ detection of single RNA molecules ( Figure 2e) Genotyping and sequencing. Currently, CS oligonucleotides are the main source of PLP, but little is known whether the detection efficiency, which is positively correlated with RNA resolution, is affected by the quality of the oligonucleotides. Using purer PECAN oligonucleotides ( Figure 2 ad), we have conducted a preliminary exploration of this. According to the Human Protein Atlas database (www.proteinatlas.org), in the breast cancer cell line MCF-7, the expression level of HER2 mRNA was reported to be low (nTPM = 4.8). Using CS PLP, we recorded an average number of RCPs per MCF-7 cell of 9.3 (n = 283). Fig.14 ), the number of detected increased to 18.8 (n = 316), which is equivalent to a 102% increase in detection efficiency ( Figure 2 fg). Similarly, in the second cell line SK-BR-3, which has lower CCNB1 expression, the average number of RCPs detected per cell increased from 3.7 in CS PLP (n=787) to 5.3 in PECAN PLP (n=639), representing a 43% increase in efficiency ( Figure 2 fg). To further investigate the efficiency during multiplexed in situ RNA testing of routine clinical samples, we turned to formalin-fixed paraffin-embedded (FFPE) breast cancer tissue sections classified as HER2-positive by immunohistochemistry (IHC) in the diagnostic laboratory and simultaneously examined four transcripts on two consecutive slides, one for CSPLP and the other for PECAN PLP ( Figure 2 hi). These RNAs included HER2, MKI67, ESR1, and PGRR, which correspond to the conventional IHC tested breast cancer biomarkers Her-2, Ki-67, ER, and PR, respectively. Both PLPs detected relatively high expression of HER2 RNA in tissue sections, with PECAN PLP showing an efficiency that was 62% higher than that of CS PLP ( Figure 2 hi). At the same time, as expected, both PLPs detected very low expression of MKI67, ESR1, and PGR in HER2-positive tissue sections ( Fig.15 However, for these three RNAs, the detection efficiency of PECAN PLP was improved by >100% compared with CS PLP, which was clearly demonstrated by statistical analysis (P<0.0001) ( Figure 2 i). In summary, our preliminary study confirmed that PECAN oligonucleotides can stably improve the efficiency of RNA detection in tissues and cells as probes. The results are consistent with the purity of >98% and <65% between conventional PECAN oligonucleotides and CS oligonucleotides ( Figure 2 d). Application of Example 4 in large fragment capture for targeted sequencing. Specific capture of long genomic regions of multi-exon size (~200-1000 bp) can accurately preserve the genomic information of the sample for functional analysis of gene products and regulatory elements by targeted sequencing. To this end, long padlock or long adaptor single-stranded oligonucleotide (LASSO) probes (usually 300-500mer in length) were developed as the next generation of molecular inversion probes to overcome the problem of persistence length (rigidity) of long dsDNA during capture ( Figure 3 b) However, current synthetic methods are unable to efficiently generate such long oligomers, thus hindering our understanding of the functional significance of genes in high-quality sequences generated by large fragment capture. We believe that PECAN provides the ultimate solution for LASSO probes. As an initial proof-of-concept, we generated LASSO probes by PECAN to analyze alternative splicing in different cell lines. The gene S100P is transcribed as a single isoform in hepatocellular carcinoma 97L (but not normal liver (NL)) cells (NCBI accession number: NM_005980.3), and CYP24A1 has two validated splice variants, tv1 (NCBI accession number: NM_000782.5) and tv2 (NCBI accession number: NM_001128915.2), the former of which is only expressed in 97L, while the latter is expressed in both ( Figure 3 a). To accurately visualize these transcriptional differences, we designed LASSO probe 1 (335mer) and probe 2 (550mer) to specifically target S100P and CYP24A1 tv1, respectively. After gap filling and ligation, a 401 bp fragment in S100P and a 749 bp fragment in CYP24A1 tv1 should be captured for targeted amplification and sequencing ( Figure 3 b). We first confirmed the purity and length of PECAN LASSO 1 and 2 by dPAGE ( Figure 3 c). After amplification, agarose gel revealed that a fragment of the expected length was captured by PECAN LASSO 1 from 97L but not NL ( Figure 3 d). This fragment was later confirmed to be derived from S100P by sequencing ( Figure 3 e, Fig.16a). Interestingly, for capture by PECAN LASSO 2, in addition to the expected fragment, a second fragment with a size of ∼200 bp or more was revealed from 97L (indicated by *), but not from NL ( Figure 3 d). The expected fragment belongs to CYP24A1tv1, while the unexpected fragment actually comes from CYP24A1 tvX1 (NCBI accession number: XM_005260304.5) ( Figure 3 e, Fig.16 bc), another isoform of CYP24A1 that has been predicted bioinformatically but not experimentally validated in 97L. CYP24A1 tvX1 differs from CYP24A1 only by a 172 bp insertion between exons 11 and 12 and can therefore be captured by PECAN LASSO 2, which was originally designed to hybridize to exons 10 and 12 to specifically capture CYP24A1 tv1 ( Figure 3 b). By using PECANLASSO 2, we further screened a series of hepatoma cell lines to explore the splicing isoforms of CYP24A1 and found that CYP24A1 tv1 and tvX1 were expressed in 97L, 97H, LM3 and HepG2 cells, but not in Hu7 cells, which demonstrated the feasibility of PECAN oligonucleotides. Application of Example 5 in homology-directed genome editing. The rapid development of genome editing technologies, especially CRISPR / Cas9 systems, has enabled the efficient generation of knockout (KO) cells and mouse models through error-prone nonhomologous end joining. However, the efficiency of precise sequence insertion (e.g., knock-in (KI) of a reporter gene or recombinase) and precise sequence replacement (e.g., conditional knockout allele of an exon flanked by LoxP sites) by using exogenous DNA donors as templates for homology-directed repair (HDR) is very poor, creating a barrier to the most useful genetic engineering models in biomedical research. Recent studies have revealed that long kilobase ssDNA can be used as an attractive alternative to its equivalent dsDNA HDR template (HDRT) to systematically improve the efficiency of genome editing, but a robust synthetic method to generate oligonucleotides of such size is lacking. We speculated that PECAN, which can synthesize arbitrary oligonucleotides up to 7000mers, could address the challenging source of HDRT ssDNA. To test our hypothesis, we performed comparative analysis of long DNA donors with equivalent sequences but different formats (including dsDNA prepared by PCR amplification and ssDNA prepared by kit or PECAN) to introduce fluorescent reporter genes into human cell lines ( Figure 4). We choose Guide-it TM Long ssDNA strand enzyme kit, selectively degrades one of the two strands in dsDNA for the generation of KitssDNA. Based on previous reports, we designed HDRTs with ~400mer homology arms to maximize KI efficiency, resulting in a series of ~1500bp or ~1500nt HDRTs to fuse fluorescent tags (~700nt) to housekeeping genes TUBA1B, CLTA, FBL, or RAB11A in Hek293T cells. dPAGE analysis confirmed that the purity of all PECAN-1500mer HDRT oligonucleotide products was much higher than that of Kit products ( Figure 4 b, Fig.17 ). When electroporated into Hek293T cells, PECAN HDRT caused negligible loss of viability ( Fig.18 ). After fluorescence-activated cell sorting, live cell imaging showed that all KIs delivered via dsDNA HDRT had significant off-target effects, and KIs delivered via Kit HDRT had significant off-target effects at the FBL locus. In contrast, all KIs delivered via PECAN HDRT had no off-target effects, indicating that PECAN HDRT is the most specific KI donor among the three ( Figure 4 c). These results are consistent with quantitative off-target measurements performed by omitting the single guide RNA (sgRNA) in the CRISPR system, where PECAN HDRT resulted in <1% off-target integration at all loci, including the FBL locus, while >5% and >95% off-target were detected in KIs performed with Kit HDRT and dsDNA HDRT, respectively ( Figure 4 d). We infer that the low off-target rate of PECAN HDRT is due to the high quality of these DNAs, especially the absence of dsDNA fragments in the oligonucleotide products compared with Kit HDRT and dsDNA HDRT, because dsDNA donors can lead to high rates of nonspecific KI through potential nonhomologous integration of dsDNA at random double-strand breaks. Next, we selected TUBA1B genes that showed <1% off-target in all three types of HDRT ( Figure 4 d) to assess apparent KI efficiency (percentage of GFP-positive cells). In Hek293T cells, we detected that PECAN HDRT resulted in ~28-41% GFP KI, which is >2-fold more efficient than Kit HDRT and exceeds the efficiency of dsDNA HDRT for both sense and antisense strands ( Figure 4e). In H9 cells that are not susceptible to KI, we achieved an apparent efficiency of 14.5% using PECAN HDRT, and the efficiency gradually decreased from PECAN HDRT to Kit HDRT to dsDNA HDRT, with a 3-fold fluctuation between the best and the minimum ( Figure 4 e). We further characterized the on-target GFP frequency (specificity) at the TUBA1B locus in GFP-positive Hek293T cells by digital droplet PCR assay, reaching 98.46% using PECAN HDRT and 84.91% using KitHDRT ( Fig.19 ). The high KI efficiency and specificity of PECAN donors enabled us to easily construct high-quality cell models carrying fluorescent reporter genes and dual KIs ( Figure 4 f). Using these stain-free cell models, we conducted preliminary studies on the internalization of tetrahedral DNA nanostructures (TDNs) in mammalian cells, which have been widely used as carriers for drug delivery in DNA nanotechnology. Under confocal microscopy, we observed that cyanine 5 (Cy5)-labeled TDNs internalized GFP-labeled microtubules ( Figure 4 g) Colocalization provides support for the microtubule-dependent transport of TDN in cells. Interestingly, we also found that Cy5-TDN overlaps with RFP-labeled clathrin at different stages of the cell cycle ( Figure 4 h), which means that in addition to the reported uptake of caveolin, clathrin may also be involved in the endocytosis of TDN via the clathrin-microtubule pathway. As further work is needed to fully reveal the internalization mechanism of TDN, it is undoubtedly possible that the different subcellular localizations of each reporter fusion protein ( Figure 4 h) The revealed precise KI of reporter genes using PECAN HDRT can provide a clean and clear endogenous reference for high-quality cell imaging. Example 6 Application in DNA-based data storage. The exceptional density, durability, longevity, and energy efficiency make DNA also an interesting medium for storing digital information in our era of big data. Several DNA-based storage architectures and platforms have been established using pools of oligonucleotides <300mer that can be synthesized chemically or enzymatically. However, the cumulative costs of error correction, subsegment reassembly, etc. on larger data payloads make current DNA-based storage systems uncompetitive compared to existing flash memory technologies. However, this situation may change with the advent of PECAN, which can provide extremely long (~7000mer) high-quality oligonucleotides as giant building blocks to reduce the scheme overhead in DNA-based storage systems. As a proof of concept, we selected the 6.75KB "Milk Crown" JPG image for the storage of ultra-long PECAN oligonucleotides ( Figure 5 a). Based on the reported encoding strategy, we converted the image file into an 81,000-bit bitstream that can be encoded by a 40,500-nt DNA sequence. Such encoding provides a net information density of 1.33 bits / nt, which is comparable to most existing strategies ( Figure 5 b). We then segmented the 40,500 nt sequence into six 6,790 nt oligonucleotides, each containing a 6,750 nt codeword domain and a unique, strand-specific 40 nt address for indexing. After PECAN generation and oligonucleotide quality checks, each 6,790mer strand was stored separately using a physical address ( Figure 5 a) To retrieve the image file, we sampled each individual oligonucleotide and created a mix of oligonucleotides for sequencing on an Oxford PromethION Nanopore sequencer. Sequencing data was generated and decoded within minutes, resulting in the recovery of the image with 100% accuracy. It can be seen that the PECAN oligonucleotide-assisted storage system has several advantages ( Figure 5 b). First, the main long payload region on the PECAN oligonucleotide ensures the coding efficiency of the system by reducing the overhead redundancy (the percentage of non-payload code) to 0.6% (nearly 20-60 times lower than the overhead redundancy of most known DNA-based storage systems). Second, the PECAN oligonucleotide can be produced in large quantities (gram quantities achieved by laboratory fermenters) with high fidelity (derived from faithful in vivo replication). Fig.12 ), thus supporting a practical and economical write and read mode, i.e., write once, generate a large number of data copies at a lower cost and lower error rate per data copy, and read multiple times in a PCR-independent manner. Thirdly, although the individual synthesis of oligonucleotides by PECAN initially increases production costs compared to oligonucleotide library synthesis, the physical address of each oligonucleotide thus obtained facilitates random access, enabling selective data reading independent of PCR, an advantage that will inevitably amortize the cost. Last but not least, the ~7000mer ultra-long PECAN oligonucleotides allow us to fully utilize the most advanced nanopolishing platform to reduce sequencing costs. Although preferred embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that these embodiments are provided by way of example only. The present invention is not limited to the specific embodiments provided in the specification. Although the present invention has been described with reference to the foregoing description, the description and illustration of the embodiments herein are not restrictive. Without departing from the present invention, many variations, changes and alternatives will occur to those skilled in the art. In addition, it should be understood that all aspects of the present invention are not limited to the specific descriptions, configurations or relative proportions set forth herein, which depend on various conditions and variables. It should be understood that various alternatives to the embodiments of the present invention described herein may be used to practice the present invention. Therefore, it is contemplated that the present invention should also cover any such alternatives, modifications, variations or equivalents. The appended claims are intended to define the scope of the present invention, and thereby cover methods and structures within the scope of these claims and their equivalents.

Claims

1. A system comprising one or more catalytic domains and one or more substrate domains, wherein the catalytic domain comprises a 13PD catalytic domain sequence, the catalytic domain cleaves the substrate domain at a cleavage site, and the substrate domain comprises a base selected from A, C and G on the 3' side of the cleavage site.

2. The system of claim 1, wherein the system comprises one or more catalytic nucleic acids, and the catalytic nucleic acids comprise one or more of the catalytic domains.

3. The system of claim 2, wherein the system comprises one or more substrate nucleic acids, and the substrate nucleic acids comprise one or more of the substrate domains.

4. The system according to any one of claims 2 to 3, wherein one or more of the catalytic nucleic acids and one or more of the substrate nucleic acids are separated and / or conjugated.

5. The system according to any one of claims 1 to 4, wherein the system further comprises one or more binding domains, and the binding domains are located on both sides and / or inside the catalytic domain and / or the substrate domain.

6. The system of claim 5, wherein the catalytic nucleic acid comprises one or more binding domains A, the substrate nucleic acid comprises one or more binding domains B, and the binding domains A are capable of binding to the binding domains B.

7. The system according to any one of claims 5 to 6, wherein the catalytic nucleic acid comprises a 5' The substrate nucleic acid comprises a binding domain A-5 on the 5' side of the substrate domain and a binding domain A-3 on the 3' side of the catalytic domain, the substrate nucleic acid comprises a binding domain B-5 on the 5' side of the substrate domain and a binding domain B-3 on the 3' side of the substrate domain, and the binding domain A-5 is complementary to the binding domain B-3 and / or the binding domain A-3 is complementary to the binding domain B-5.

8. The system according to any one of claims 1 to 7, wherein the 13PD comprises 13PD1, 13PD2, 13PD3, 13PD4 and / or their mutants.

9. The system according to any one of claims 1 to 8, wherein the catalytic domain comprises the sequence of SEQ ID NO:

17.

10. The system of any one of claims 1 to 9, wherein the catalytic domain comprises nucleic acid hydrolysis activity.

11. The system according to any one of claims 1 to 10, wherein the substrate domain comprises the sequence of SEQ ID NO:

18.

12. The system according to any one of claims 1 to 11, wherein the substrate domain comprises A, C or G at the 3' end of the substrate domain.

13. A nucleic acid comprising one or more catalytic domains and one or more substrate domains, wherein the catalytic domain comprises a 13PD catalytic domain sequence, the catalytic domain cleaves the substrate domain at the cleavage site, and the substrate domain comprises a base selected from A, C and G on the 3' side of the cleavage site.

14. The nucleic acid according to claim 13, wherein the nucleic acid further comprises one or more binding domains, and the binding domains are located on both sides and / or inside the catalytic domain and / or the substrate domain.

15. The nucleic acid according to claim 14, wherein the nucleic acid comprises one or more binding domains A located on both sides of the catalytic domain, the nucleic acid comprises one or more binding domains B located on both sides of the substrate domain, and the binding domain A is capable of binding to the binding domain B.

16. A nucleic acid according to any one of claims 14 to 15, wherein the nucleic acid comprises a binding domain A-5 at the 5' side of the catalytic domain and a binding domain A-3 at the 3' side of the catalytic domain, the nucleic acid comprises a binding domain B-5 at the 5' side of the substrate domain and a binding domain B-3 at the 3' side of the substrate domain, and the binding domain A-5 is complementary to the binding domain B-3 and / or the binding domain A-3 is complementary to the binding domain B-5.

17. The nucleic acid according to any one of claims 13 to 16, wherein the 13PD comprises 13PD1, 13PD2, 13PD3, 13PD4 and / or their mutants.

18. The nucleic acid of any one of claims 13 to 17, wherein the catalytic domain comprises the sequence of SEQ ID NO:

17.

19. The nucleic acid of any one of claims 13 to 18, wherein the catalytic domain comprises nucleic acid hydrolysis activity.

20. The nucleic acid of any one of claims 13 to 19, wherein the substrate domain comprises the sequence of SEQ ID NO:

18.

21. The nucleic acid according to any one of claims 13 to 20, wherein the substrate domain comprises a 3' A, C, or G on the left side.

22. A vector comprising the system of any one of claims 1 to 12, and / or the nucleic acid of any one of claims 13 to 21.

23. A cell comprising the system of any one of claims 1 to 12, the nucleic acid of any one of claims 13 to 21 and / or the vector of claim 22.

24. A composition comprising the system of any one of claims 1 to 12, the nucleic acid of any one of claims 13 to 21, the vector of claim 22 and / or the cell of claim 23.

25. A kit comprising the system of any one of claims 1 to 12, the nucleic acid of any one of claims 13 to 21, the vector of claim 22, the cell of claim 23 and / or the composition of claim 24.

26. A method for preparing a product, comprising providing the system of any one of claims 1 to 12, the nucleic acid of any one of claims 13 to 21, the vector of claim 22, the cell of claim 23, the composition of claim 24 and / or the kit of claim 25.

27. A product prepared according to the method of claim 26.

28. The product of claim 27, comprising a nucleic acid.

29. A combination comprising providing a mixture comprising about 1 mM to 2 mM Zn 2+ and about 5mM to 20mM Mn 2+ conditions.

30. The combination according to claim 29, comprising providing a mixture comprising about 1 mM Zn 2+ and about 5mM Mn 2+ conditions.

31. The combination according to any one of claims 29 to 30, comprising about 1 mM Zn 2+ and about 5mM Mn 2+ 。 32. A method for preparing a product, the method comprising providing a combination according to any one of claims 29 to 31 and providing a 5' nucleic acid cutter and a 3' nucleic acid cutter.

33. The method of claim 32, wherein the 5' nucleic acid cutter comprises DNase I capable of generating a 3' cleavage product.

34. The method according to any one of claims 32 to 33, wherein the 5' nucleic acid cutter is located at the 5' side of the product.

35. The method according to any one of claims 32 to 34, wherein the 5' nucleic acid cutter comprises 13PD and mutants thereof.

36. The method of any one of claims 32 to 35, wherein the 3' nucleic acid cutter comprises DNase II capable of generating a 5' cutter product.

37. The method according to any one of claims 32 to 36, wherein the 3' nucleic acid cutter is located at the 3' side of the product.

38. The method according to any one of claims 32 to 37, wherein the 3' nucleic acid cutter comprises II-R1 and mutants thereof.

39. The method according to any one of claims 32 to 38, wherein the 3' nucleic acid cutter comprises II-R1a, II-R1b, II- R1c, II-R1d and their mutants.

40. A product prepared according to the method of any one of claims 32 to 39.

41. The product of claim 40, comprising a nucleic acid.

42. A method for nucleic acid detection, the method comprising providing a product as described in any one of claims 27 to 28 and 40 to 41.

43. A method of sequencing, the method comprising providing a product as described in any one of claims 27 to 28 and 40 to 41.

44. A genetic engineering method comprising providing a product as claimed in any one of claims 27 to 28 and 40 to 41.

45. A method of data storage comprising providing a product as claimed in any one of claims 27 to 28 and 40 to 41.